Stock Analysis on Net
Stock Analysis on Net

Boston Scientific Corp. (NYSE:BSX)

$22.49

This company has been moved to the archive! The financial data has not been updated since May 4, 2023.

Common-Size Balance Sheet: Liabilities and Stockholders’ Equity

Paying user area

Try for free

Boston Scientific Corp. pages available for free this week:

The data is hidden behind: . Unhide it.

Get access

This is a one-time payment. There is no automatic renewal.

We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Apple Pay Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Boston Scientific Corp., common-size consolidated balance sheet: liabilities and stockholders’ equity

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Current debt obligations
Accounts payable
Legal reserves
Payroll and related liabilities
Rebates
Contingent consideration
Other
Accrued expenses
Deferred revenue
Licensing arrangements
Taxes payable
Liabilities held for sale
Other
Other current liabilities
Current liabilities
Long-term debt
Deferred tax liabilities
Accrued income taxes
Legal reserves
Contingent consideration
Licensing arrangements
Long-term operating lease liabilities
Deferred revenue
Other
Other long-term liabilities
Long-term liabilities
Total liabilities
Preferred stock, $0.01 par value
Common stock, $0.01 par value
Treasury stock, at cost
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income, net of tax
Stockholders’ equity
Total liabilities and stockholders’ equity

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

Balance sheet item Description The company
Current liabilities Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. Boston Scientific Corp. current liabilities as a percentage of total liabilities and stockholders’ equity increased from 2020 to 2021 but then decreased significantly from 2021 to 2022.
Long-term liabilities Amount of obligation due after one year or beyond the normal operating cycle, if longer. Boston Scientific Corp. long-term liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2020 to 2021 and from 2021 to 2022.
Total liabilities Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future. Boston Scientific Corp. total liabilities as a percentage of total liabilities and stockholders’ equity decreased from 2020 to 2021 and from 2021 to 2022.
Stockholders’ equity Total of all stockholders’ equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity stockholders’ equity attributable to the parent excludes the amount of stockholders’ equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity. Boston Scientific Corp. stockholders’ equity as a percentage of total liabilities and stockholders’ equity increased from 2020 to 2021 and from 2021 to 2022.